



NEWS RELEASE

NIAID Completes Dose Range-Finding Study and Confirms DEF201 is Well Tolerated in Test Animals

Web Site Release

March 28, 2012

Toronto - Defyrus Inc. today announced the results from a study report entitled "Dose Range-Finding Study After A Single intranasal Administration of DEF201 to Male and Female Golden Syrian Hamsters", The objective of this study was to determine appropriate intranasal dose levels of DEF201, an adenovirus vector that encodes human consensus interferon alpha (IFN α), when administered to hamsters for use in subsequent definitive safety studies. The study concluded that "intranasal administration of DEF201 to hamsters was well tolerated at doses up to 2.5×10^9 pfu" [the projected human dose] and "the no observed adverse effect level (NOAEL) was determined to be 1×10^8 pfu. The maximum tolerated dose (MTD) was estimated to be above 2.5×10^9 pfu." Exploring the human IFN α gene expression, "using an enzyme-linked immunosorbent assay (ELISA), human IFN α was detected with a dose-dependence in the serum of 1 of 5 low-dose males, in 4 of 5 mid-dose males and in all 5 high-dose males, and in none of the vehicle or vector control animals."

"Hamsters were selected as our animal model, in consultation with the Food and Drug Administration, because hamsters respond well to the human IFN α produced by DEF201", stated Dr. Jeffrey Turner, President & CEO, Defyrus Inc., "we now know that DEF201 is well tolerated in hamsters even with the entire adult human dose administered to a tiny (100 g) animal. Based on these positive results, we are now moving toward an IND-enabling GLP biodistribution study in hamsters with DEF201 to collect data for a future regulatory submission".

About Defyrus Inc.

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom, Canada and Singapore to develop broad spectrum anti-viral drugs and immune stimulator to improve vaccine performance as medical countermeasures to viral threats of military and public health interest. www.defyrus.com

This study has been partially funded by NIAID/DMID Contract 110221.

###

For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com